Pathology News

Pathology News is your go-to podcast for the latest insights and innovations in pathology. We explore digital pathology, molecular diagnostics, and more, featuring conversations with industry experts and leaders. Whether you're a pathologist or simply interested in the future of diagnostics, this podcast keeps you informed on the trends shaping the field. Tune in for expert perspectives and practical knowledge to enhance workflows and advance patient care.

Pathology News is a news podcast hosted by Unknown Host, with 30 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts Pathology News, a news show with 30 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #21

  Beyond the Diagnosis: How the TIA Centre Is Advancing AI-Powered Risk Prediction in Oral Dysplasia

  Jul 9, 202638 minS1

  In this episode, Sidney Ocanagil-Tunstall is joined by Dr Adam Shephard, Assistant Professor at the University of Warwick's Tissue Image Analytics (TIA) Centre, and Dr Hanya Mahmood, Senior Clinical Lecturer and Honorary Consultant Oral Surgeon at the University of Sheffield, to explore how artificial intelligence is transforming the diagnosis and management of oral epithelial dysplasia (OED). The conversation focuses on OYDN, an AI-powered computational pathology model developed through a collaboration between the TIA Centre and the University of Sheffield. Adam and Hanya discuss how the technology supports more objective diagnosis, improves risk stratification for patients at risk of developing oral cancer, and is helping uncover novel digital biomarkers that could shape future treatment strategies. The discussion broadens into the challenges of translating AI from research into routine clinical practice, exploring the importance of explainable AI, robust validation, clinician confidence, and NHS adoption. Looking ahead, the guests share their vision for how AI can support pathologists, standardise clinical decision-making, and ultimately improve outcomes for patients through earlier, more accurate intervention.

  ListenShow Notes
• 

  Episode #20

  Cancer Research UK: Scanner Selection, Image Quality and the Future of AI

  Jul 7, 202626 minS1

  In this episode, Sidney Ocanagil-Tunstall continues the conversation with Dr Julia Jones, Elsa Santos and Cara Brodie from the Cancer Research UK Cambridge Institute, focusing on the technologies underpinning modern digital pathology workflows. The discussion explores how the team evaluates and procures whole slide scanners, balancing image quality, flexibility and downstream compatibility over speed alone. They also examine the growing importance of colour standardisation across scanning platforms, the challenges it presents for image analysis, and how AI could help overcome variability to deliver more robust and reproducible results. Looking ahead, the conversation turns to the future of multimodal imaging, data integration and artificial intelligence, alongside practical advice for researchers adopting new technologies in digital pathology and spatial biology.

  ListenShow Notes
• 

  Episode #19

  Cancer Research UK: Driving Innovation in Digital Pathology and Spatial Biology

  Jun 30, 202621 minS1

  In this episode, Sidney Ocanagil-Tunstall visits the Cancer Research UK Cambridge Institute to explore how digital pathology and spatial biology are transforming cancer research. Joined by Dr Julia Jones, Scientific Manager for In Situ Hybridisation, alongside Senior Scientific Associates Elsa Santos and Cara Brodie, the conversation examines the Institute’s long-standing commitment to innovation, from early adoption of digital pathology workflows to the integration of advanced spatial omics technologies. The discussion covers image analysis, multiplex assays, multimodal approaches combining RNA and protein detection, and the growing role of spatial biology in understanding the tumour microenvironment. The team also reflects on the practical challenges of implementation, including costs, technology selection, collaboration, and the importance of shared expertise in driving the next generation of cancer research.

  ListenShow Notes
• 

  Episode #18

  Beyond the PSA: How Proclarix Is Supporting Smarter Clinical Decisions - Episode 2

  Jun 23, 202618 minS1

  In this episode, Sidney Ocanagil-Tunstall continues the conversation with Dr Asif Naseem, GP and specialist in preventative healthcare and men's health, and Dr Beat Rheiner, CEO of Proteomedix, this time turning to what a better diagnostic pathway could actually look like in practice. Building on the challenges of PSA testing explored in Episode 1, the discussion moves into the role of emerging tools like Proclarix in supporting smarter clinical decision-making. Asif shares his real-world experience using Proclarix as a private GP, including how it has helped him identify patients who may benefit from further investigation, and those who can safely avoid unnecessary downstream procedures. The conversation broadens into a wider discussion around diagnostics implementation and adoption, exploring the relationship between laboratory and clinician as part of the same clinical decision-making process, and why awareness of such diagnostic tools remains one of the most important barriers to overcome. As Asif puts it: new tools need to be more accessible, more widely understood, and correctly used. Proclarix is a blood-based test which works in the PSA "grey zone" of 2-10ng/ML to better stratify risk of clinically significant prostate cancer.

  ListenShow Notes
• 

  Episode #17

  Rethinking PSA Testing: Navigating the Prostate Cancer Decision Zone - Episode 1

  Jun 16, 202625 minS1

  In this episode, Sidney Ocanagil-Tunstall is joined by Dr Asif Naseem, GP and specialist in preventative healthcare and men's health, alongside Dr Beat Rheiner, CEO of Proteomedix. Together, they discuss the role of PSA testing in current prostate cancer pathways, why many patients fall into a diagnostic “gray zone,” and how emerging approaches could improve early detection and reduce uncertainty for both clinicians and patients. The conversation explores the importance of personalised risk assessment, the impact of false positives and false negatives, and how new diagnostic tools may help identify clinically significant cancers earlier while supporting more efficient, patient-centred care.

  ListenShow Notes

Recent guests on Pathology News. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.